Pharmacokinetic and Pharmacodynamic Interactions of Oral Midazolam with Ketoconazole, Fluoxetine, Fluvoxamine, and Nefazodone

Journal of Clinical Pharmacology

Volumn 43, Issue 11, 2003, Pages 1274-1282

  Lam, Y W Francis ^a,c   Alfaro, Cara L ^a,c,d   Ereshefsky, Larry ^a,b,c   Miller, Michael ^b  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^d CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Cytochrome P450 3A; Midazolam; Nefazodone; Selective serotonin reuptake inhibitors

Indexed keywords

CYP3A PROTEIN, HUMAN; CYTOCHROME P450; CYTOCHROME P450 3A4; FLUOXETINE; FLUVOXAMINE; KETOCONAZOLE; MIDAZOLAM; NEFAZODONE; TRIAZOLE DERIVATIVE;

ADULT; ANALYSIS OF VARIANCE; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CALCULATION; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG INTERACTION; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; METABOLISM; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS;

ADMINISTRATION, ORAL; ADULT; ANALYSIS OF VARIANCE; AREA UNDER CURVE; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; FEMALE; FLUOXETINE; FLUVOXAMINE; HUMANS; KETOCONAZOLE; MALE; MIDAZOLAM; TRIAZOLES;

EID: 0142040171     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270003259216     Document Type: Article

References (27)

1. Thummel KE, Wilkinson GR: In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol 1998;38:389-430.
2. Venkatakrishnan K, Greenblatt DJ, von Moltke LL, Shader RI: Alprazolam is another substrate for human cytochrome P450-3A isoforms [letter]. J Clin Psychopharmacol 1998;18:256.
3. Gorski JC, Jones DR, Hamman MA, Wrighton SA, Hall SD: Biotransformation of alprazolam by members of the human cytochrome P4503A subfamily. Xenobiotica 1999;29:931-944.
4. Fleishaker JC, Hulst LK: A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine. Eur J Clin Pharmacol 1994;46:35-39.
5. Barbhaiya RH, Shukla UA, Kroboth PD, Greene DS: Coadministration of nefazodone and benzodiazepines: II. A pharmacokinetic interaction with triazolam. J Clin Psychopharmacol 1995;15:320-326.
6. Greene DS, Salazar DE, Dockens RC, Kroboth P, Barbhaiya RH: Coadministration of nefazodone and benzodiazapines: III. A pharmacokinetic interaction with alprazolam. J Clin Psychopharmacol 1995;15:399-408.
7. Greenblatt DJ, Preskorn SH, Cotreau MM, Horst WD, Harmatz JS: Fluoxetine impairs clearance of alprazolam but not of clonazepam. Clin Pharmacol Ther 1992;52:479-486.
8. Wright CE, Lasher-Sisson TA, Steenwyk RC, Swanson CN: A pharmacokinetic evaluation of the combined administration of triazolam and fluoxetine. Pharmacotherapy 1992;12:103-106.
9. Greenblatt DJ, von Moltke LL, Schmider J, Harmatz JS, Shader RI: Inhibition of human cytochrome P450-3A isoforms by fluoxetine and norfluoxetine: in vitro and in vivo studies. J Clin Pharmacol 1996;36:792-798.
10. Lasher TA, Fleishaker JC, Steenwyk RC, Antal EJ: Pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluoxetine. Psychopharmacology 1991;104:323-327.
11. Gorski JC, Hall SD, Jones DR, VandenBranden M, Wrighton SA: Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol 1994;47:1643-1653.
12. Thummel KE, Shen DD, Podoll TD, et al: Use of midazolam as a human cytochrome P4503A probe: 1. In vitro-in vivo correlation in liver transplant patients. J Pharmacol Expl Ther 1994;271:549-556.
13. Ghosal A, Satoh H, Thomas PE, et al: Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cDNA-expressed human cytochrome P450. Drug Metab Dispos 1996;24:940-947.
14. Maenpaa J, Hall SD, Ring BJ, et al: Human cytochrome P450 3A (CYP3A) mediated midazolam metabolism: the effect of assay conditions and regioselective stimulation by alpha-naphthoflavone, terfenadine and testosterone. Pharmacogenetics 1998;8:137-155.
15. von Moltke LL, Greenblatt DJ, Schmider J, et al: Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents. J Clin Pharmacol 1996;36:783-791.
16. Steedman SL, Koonce JR, Wynn JE, Brahen NH: Stability of midazolam hydrochloride in a flavored, dye-free oral solution. Am J Hosp Pharm 1992;49:615-618.
17. Smith A: Symbol Digit Modalities Test. 6th ed. Los Angeles: Western Psychological Services, 1982.
18. Bergstrom RF, Peyton AL, Lemberger L: Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. Clin Pharmacol Ther 1992;51:239-248.
19. Jamis-Dow CA, Collins JM, Klecker RW, Blake DS, Watkins PB, Pearl ML: Predicting drug interactions in vivo from experiments in vitro: human studies with paclitaxel and ketoconazole. Am J Clin Oncol 1997;20:592-599.
20. Amchin J, Ereshefsky L, Zarycranski W, Taylor K, Albano D, Klockowski PM: Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe. J Clin Pharmacology 2001;41:443-451.
21. Tsunoda SM, Velez RL, von Moltke LL, Greenblatt DJ: Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole. Clin Pharmacol Ther 1999;66:461-471.
22. Lee JI, Chaves-Gnecco D, Amico JA, Kroboth PD, Wilson JW, Frye RF: Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping. Clin Pharmacol Ther 2002;72:718-728.
23. Olkkola KT, Backman JT, Neuvonen PJ: Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994;55:481-485.
24. Lam YWF, Gaedigk A, Ereshefsky L, Alfaro C, Simpson J: CYP2D6 inhibition by SSRIs: analysis of achievable plasma concentrations and the effect of ultra-rapid metabolism at CYP2D6. Pharmacotherapy 2002;22:1001-1006.
25. Kashuba ADM, Nafziger AN, Kearns GL, et al: Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6 and CYP3A as determined by phenotyping. Clin Pharmacol Ther 1998;64:257-268.
26. Amsterdam JD, Fawcett J, Quitkin FM, Reimherr FW, Rosenbaum JF, Michelson D, et al: Fluoxetine and norfluoxetine plasma concentrations in major depression: a multicenter study. Am J Psychiatry 1997;154:963-969.
27. Beasley CM, Bosomworth JC, Wernicke JF: Fluoxetine: relationship among dose, response, adverse events, and plasma concentrations in the treatment of depression. Psychopharmacol Bull 1990;26:18-24.